Prothena (PRTA)
NASDAQ:PRTA
PRTA Stock Chart & Stats
$10.50
<$0.01(0.07%)
At close: 4:00 PM EST
$10.50
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$4.32 - $11.69
Previous CloseN/A
Volume58.73K
Average Volume (3M)732.47K
Market Cap
$565.25M
Enterprise Value$271.58M
Total Cash (Recent Filing)$307.53M
Total Debt (Recent Filing)$13.86M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 13, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding53,832,980
10 Day Avg. Volume686,318
30 Day Avg. Volume732,465
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.83
Price to Sales (P/S)53.08
P/FCF Ratio-3.14
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue28.04
Enterprise Value/Gross Profit-13.45
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$21.50Price Target Upside104.76% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.78
Revenue Forecast (FY)$111.77M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyOpen-label extension results indicate the drug's slowing of motor and functional decline versus an external comparator was sustained and became larger, strengthening the underlying clinical signal for later-stage development.
Partnerships And Non-dilutive FinancingAchievement of a substantial clinical milestone payment from a major partner tied to enrollment progress provides non-dilutive capital and serves as external endorsement of the science and development plan.
Platform Delivery And Preclinical ValidationCYTOPE together with transferrin receptor-mediated delivery enables transport of large therapeutic molecules into cells and across the blood-brain barrier while avoiding membrane-disrupting toxicity, supported by preclinical reductions in toxic aggregates and restoration of normal protein function in disease models.
Bears Say
Intellectual Property StrengthQuestions about the strength and scope of the platform-specific patent estate raise the possibility of competitive challenges or limits on commercialization as the technology moves toward clinical validation.
Platform Generalizability RiskUncertainty about whether the delivery platform can be applied to other intracellular proteinopathies creates a risk that success in one indication may not translate to broader therapeutic opportunities.
Prothena News
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $4.32 and its highest was $11.69 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $565.25M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is May 13, 2026 which is in 31 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Feb 19, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.559 by $0.159.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.35.
How many shares outstanding does Prothena have?
Prothena has 53,832,980 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.559. Following the earnings report the stock price went down -0.111%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.50 (104.76% Upside)
$21.50 (104.76% Upside)
Hedge Fund Trend
Decreased
By 25.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.39%
12-Months-Change
Fundamentals
Return on Equity
-73.00%
Trailing 12-Months
Asset Growth
-40.27%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
PRTA Company Deck
PRTA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.View all PRTA earnings summariesPRTA Stock 12 Month Forecast
Average Price Target
$21.50
▲(104.76% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
XOMA Royalty Corporation
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Ownership Overview
12.80% Insiders
19.44% Mutual Funds
22.04% Other Institutional Investors
36.41% Public Companies and
Individual Investors